Destiny Pharma announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to XF-73 (exeporfinium chloride) for the prevention of post-surgical infections caused by Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA).
Data from four Phase 1/2a studies has shown that XF-73 is rapidly bactericidal, reducing the number of bacteria in the nose quickly. A clinical trial for XF-73, sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is ongoing and expected to be completed shortly.
XF-73 (exeporfinium chloride) is a novel, synthetic drug with anti-bacterial activity against a broad range of bacteria.
For more information visit Destinypharma.com.